AC Immune: Q3 Earnings Snapshot
AC Immune SA reported a Q3 loss of $10.8 million, or 16 cents per share, with revenue of $4 million. Shares closed at $2.09, down from $3.18 a year ago, according to the company.
AC Immune SA
AC Immune is a clinical-stage biopharmaceutical company developing medicines and diagnostic tools for neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease. It uses its SupraAntigen platform to develop biologic and immunotherapy candidates, and its Morphomer platform to develop small molecules and PET imaging agents. Its programs target proteins including amyloid beta, Tau, alpha-synuclein, NLRP3 and TDP-43. Products and candidates include active immunotherapies, monoclonal antibodies, small-molecule drugs and imaging agents intended to support diagnosis and patient selection. AC Immune makes money through collaboration and licensing agreements with pharmaceutical partners, which can provide payments and royalties, and may advance some candidates independently. Its registered office and domicile are in Ecublens, Switzerland, at the EPFL Innovation Park.
No enriched coverage for $ACIU in the last 7 days.
No SEC Form 4 filings for $ACIU in the last 30 days.
See all $ACIU insider activity →AC Immune SA reported a Q3 loss of $10.8 million, or 16 cents per share, with revenue of $4 million. Shares closed at $2.09, down from $3.18 a year ago, according to the company.
AC Immune (ACIU) reported positive week-100 data from Part 1 of its Phase 2 trial for Parkinson's vaccine ACI-7104, meeting safety, tolerability, and immunogenicity endpoints. All patients showed an antibody response, with data suggesting target engagement. The company plans to extend Part 1 and finalize Part 2 design to test clinical efficacy.
Eloxx Pharmaceuticals (ELOX) rose 20% after FDA cleared its Phase 2b trial for exaluren. Vogenx (VOGX) gained 14% post-IPO. Arcturus (ARCT) advanced 21% on pipeline updates. Zhengye (ZYBT) +7% after Nasdaq compliance. Greenwich (GLSI) +10% on extended lock-up. HeartSciences (HSCS) +8% after $1M investment. AC Immune (ACIU) +8% on Phase 1 data.
Recent ACIU coverage spans technology, earnings and regulation.
The loss and revenue miss likely pressure the stock lower.
Positive trial data could boost stock on expectations of Phase 2b/3 progression.
Early‑stage data de‑risk the program and attract further capital.
Positive early‑stage data may lift near‑term sentiment and support a short‑term price rally.
Positive safety and pharmacokinetic data may boost investor confidence and support near‑term price appreciation.
AlphAI scores every news story that mentions ACIU with an AI model for sentiment and relevance, and aggregates insider trades from AC Immune SA's SEC EDGAR Form 4 filings. Figures refresh continuously.
AC Immune SA reported a Q3 loss of $10.8 million, or 16 cents per share, with revenue of $4 million. Shares closed at $2.09, down from $3.18 a year ago, according to the company.
AC Immune (ACIU) reported positive week-100 data from Part 1 of its Phase 2 trial for Parkinson's vaccine ACI-7104, meeting safety, tolerability, and immunogenicity endpoints. All patients showed an antibody response, with data suggesting target engagement. The company plans to extend Part 1 and finalize Part 2 design to test clinical efficacy.
Eloxx Pharmaceuticals (ELOX) rose 20% after FDA cleared its Phase 2b trial for exaluren. Vogenx (VOGX) gained 14% post-IPO. Arcturus (ARCT) advanced 21% on pipeline updates. Zhengye (ZYBT) +7% after Nasdaq compliance. Greenwich (GLSI) +10% on extended lock-up. HeartSciences (HSCS) +8% after $1M investment. AC Immune (ACIU) +8% on Phase 1 data.
AC Immune (ACIU) reported positive interim Phase 1 data for ACI-19764, an oral NLRP3 inhibitor. The therapy was safe, well-tolerated, and showed dose-dependent inhibition of IL-1beta. Initial results from a cardiovascular risk cohort are expected by year-end. ACIU stock is down 4.07% to $2.47.
AC Immune SA (ACIU) shares rose 3.9% premarket after reporting positive Phase 1 trial data for ACI-19764, an NLRP3 inhibitor. The drug was safe, well-tolerated, and showed brain penetration. Phase 1b results are expected by year-end, with full results in 2027. ACI-19764 targets chronic inflammation in various diseases.
AC Immune (ACIU) shares rose 3.4% pre-open after the FDA granted Fast Track status to its ACI-7104 anti-alpha-synuclein therapy and cleared its IND. The move allows Phase 2 VacSYn trial enrollment to expand to U.S. sites. Interim 76-week Part 1 data showed a favorable safety profile. The stock was near $2.37.
AC Immune SA (ACIU) said the FDA granted Fast Track designation to its ACI-7104 anti-alpha-synuclein immunotherapy for early Parkinson’s. The drug is in the VacSYn Phase 2 trial; Part 1 interim data at 76 weeks reported safety and a 100% immunogenicity responder rate. Next steps include U.S. site expansion after IND clearance and week-100 results in H2 2026.
AC Immune SA (ACIU) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 PRESS RELEASE AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments ● Key advances across pipeline, with further near-term
AC Immune SA (NASDAQ: ACIU) reported a half-year update for June 30, 2026, highlighting Phase 2 VacSYn Part 1 full results for ACI-7104 in H2 2026, Phase 1/1b data for ACI-19764 in H2 2026, and Phase 1 PET results for ACI-19626. Cash was CHF 75.4m. Revenues were CHF 16.2m. A $12m Takeda milestone was triggered for ACI-24.
AC Immune SA (NASDAQ: ACIU) said it will present three neurodegenerative disease pipeline updates at AAIC 2026 in London (July 12–15). It plans to share early human imaging for the [18F]ACI-19626 TDP-43 PET tracer, Phase 1 data for NLRP3 inhibitor ACI-19764, and preclinical results for an alpha-synuclein aggregation inhibitor.